LISTING OF CLAIMS

Claims

1. (Currently Amended) ~~Use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of HIV infection wherein the~~ A compound of formula (I): ~~is a compound of formula~~



(I)
,

a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein

A and B each represents a radical of formula



(a) or


(b)

wherein

ring E represents phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl;

ring F represents phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl;

R^1 represents hydrogen; aryl; formyl; C_{1-6}alkylcarbonyl; C_{1-6}alkyloxycarbonyl; C_{1-6}alkyl optionally substituted with formyl, C_{1-6}alkylcarbonyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylcarbonyloxy; or C_{1-6}alkyloxyC_{1-6}alkylcarbonyl substituted with C_{1-6}alkyloxycarbonyl;

R^2 represents cyano; aminocarbonyl; mono- or di(C_{1-4}alkyl)aminocarbonyl; C_{1-6}alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl; C_{2-6}alkenyl substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl; or C_{2-6}alkynyl substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl;

X_1 represents $-NR^5$-; -NH-NH-; -N=N-; -O-; -C(=O)-; -C_{1-4}alkanediyl-; -CHOH-; -S-; -$S(=O)_p$-; -X_2-C_{1-4}alkanediyl-; –C_{1-4}alkanediyl-X_2-; or –C_{1-4}alkanediyl-X_2-C_{1-4}alkanediyl-;

X_2 represents $-NR^5$-; -NH-NH-; -N=N-; -O-; -C(=O)-; -CHOH-; -S-; or -$S(=O)_p$-;

m represents an integer of value 1, 2, 3 or 4;

R^3 represents cyano; aminocarbonyl; amino; halo; NHR^{13}; $NR^{13}R^{14}$; -C(=O)-NHR^{13}; -C(=O)-$NR^{13}R^{14}$; -C(=O)-R^{15}; -CH=N-NH-C(=O)-R^{16}; C_{1-6}alkyl optionally substituted with one or more substituents each independently selected from R^{3a}; C_{1-6}alkyloxy optionally substituted with one or more substituents each independently selected from R^{3a}; C_{1-6}alkyloxyC_{1-6}alkyl optionally substituted with

one or more substituents each independently selected from R^{3a}; C_{2-6}alkenyl optionally substituted with one or more substituents each independently selected from R^{3a}; C_{2-6}alkynyl optionally substituted with one or more substituents each independently selected from R^{3a}; -C(=N-O-R^8)-C_{1-4}alkyl; R^7 or $-X_3-R^7$;

R^{3a} represents halo, cyano, hydroxy, NR^9R^{10}, -C(=O)-NR^9R^{10}, -C(=O)-C_{1-6}alkyl, -C(=O)-O-C_{1-6}alkyl, -C(=O)-polyhaloC_{1-6}alkyl, -C(=O)-O-polyhaloC_{1-6}alkyl or R^7;

X_3 represents $-NR^5$-; -NH-NH-; -N=N-; -O-; -C(=O)-; -S-; -S(=O)$_p$-; -X_{4a}-C_{1-4}alkanediyl-; -C_{1-4}alkanediyl-X_{4b}-; $-C_{1-4}$alkanediyl-X_{4a}-C_{1-4}alkanediyl-; or -C(=N-OR^8)-C_{1-4}alkanediyl-;

X_{4a} represents $-NR^5$-; -NH-NH-; -N=N-; -C(=O)-; -S-; or -S(=O)$_p$-;

X_{4b} represents -NH-NH-; -N=N-; -O-; -C(=O)-; -S-; or -S(=O)$_p$-;

each R^4 independently represents hydroxy; halo; C_{1-6}alkyl optionally substituted with one or more substituents each independently selected from R^{4a}; C_{2-6}alkenyl optionally substituted with one or more substituents each independently selected from R^{4a};

C_{2-6}alkynyl optionally substituted with one or more substituents each independently selected from R^{4a}; C_{3-7}cycloalkyl; C_{1-6}alkyloxy; C_{1-6}alkyloxycarbonyl; C_{1-6}alkylcarbonyloxy; carboxyl; formyl; cyano; nitro; amino; mono- or di(C_{1-6}alkyl)amino; polyhaloC_{1-6}alkyl; polyhaloC_{1-6}alkyloxy; polyhaloC_{1-6}alkylthio; -S(=O)$_p$$R^6$; -NH-S(=O)$_p$$R^6$; -C(=O)$R^6$; -NHC(=O)H; -C(=O)$NHNH_2$; NHC(=O)$R^6$; C(=NH)$R^6$; or R^7;

R^{4a} represents halo, cyano, NR^9R^{10}, hydroxy or -C(=O)R^6;

R^5 represents hydrogen; aryl; formyl; C_{1-6}alkylcarbonyl; C_{1-6}alkyloxycarbonyl; C_{1-6}alkyl optionally substituted with formyl, C_{1-6}alkylcarbonyl, C_{1-6}alkyloxycarbonyl or C_{1-6}alkylcarbonyloxy; or C_{1-6}alkyloxyC_{1-6}alkylcarbonyl substituted with C_{1-6}alkyloxycarbonyl;

R^6 represents C_{1-6}alkyl, amino, mono- or di(C_{1-4}alkyl)amino or polyhaloC_{1-4}alkyl;

R^7 represents a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; or a monocyclic, bicyclic or tricyclic aromatic heterocycle; wherein each of said carbocyclic or heterocyclic ring systems may, whenever possible, optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, aminoC_{1-6}alkyl, mono or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, formyl, C_{1-6}alkylcarbonyl, C_{3-7}cycloalkyl, C_{1-6}alkyloxy, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylthio, cyano, nitro,

polyhaloC_{1-6}alkyl, polyhaloC_{1-6}alkyloxy, aminocarbonyl, -CH(=N-O-R^8), R^{7a}, -X_3-R^{7a} or R^{7a}-C_{1-4}alkanediyl-;

R^{7a} represents a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; or a monocyclic, bicyclic or tricyclic aromatic heterocycle; wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto,
C_{1-6}alkyl, hydroxyC_{1-6}alkyl, aminoC_{1-6}alkyl, mono or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, formyl, C_{1-6}alkylcarbonyl, C_{3-7}cycloalkyl, C_{1-6}alkyloxy, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylthio, cyano, nitro, polyhaloC_{1-6}alkyl, polyhaloC_{1-6}alkyloxy, aminocarbonyl, -CH(=N-O-R^8);

R^8 represents hydrogen, C_{1-4}alkyl optionally substituted with aryl, or aryl;

R^9 and R^{10} each independently represent hydrogen; hydroxy; C_{1-6}alkyl; C_{1-6}alkyloxy; C_{1-6}alkylcarbonyl; C_{1-6}alkyloxycarbonyl; amino; mono- or di(C_{1-6}alkyl)amino; mono- or di(C_{1-6}alkyl)aminocarbonyl; -CH(=NR^{11}) or R^7, wherein each of the aforementioned C_{1-6}alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C_{1-6}alkyloxy, hydroxyC_{1-6}alkyloxy, carboxyl, C_{1-6}alkyloxycarbonyl, cyano, amino, imino, mono- or di(C_{1-4}alkyl)amino, polyhaloC_{1-4}alkyl, polyhaloC_{1-4}alkyloxy, polyhaloC_{1-4}alkylthio, -S(=O)$_p$$R^6$, -NH-S(=O)$_p$$R^6$, -C(=O)$R^6$, -NHC(=O)H, -C(=O)$NHNH_2$, -NHC(=O)$R^6$,-C(=NH)$R^6$, or R^7; or

R^9 and R^{10} may be taken together to form a bivalent or trivalent radical of formula

-CH_2-CH_2-CH_2-CH_2-	(d-1);
-CH_2-CH_2-CH_2-CH_2-CH_2-	(d-2);
-CH_2-CH_2-O-CH_2-CH_2-	(d-3);
-CH_2-CH_2-S-CH_2-CH_2-	(d-4);
-CH_2-CH_2-NR^{12}-CH_2-CH_2-	(d-5);
-CH_2-CH=CH-CH_2-	(d-6); or
=CH-CH=CH-CH=CH-	(d-7);

R^{11} represents cyano; C_{1-4}alkyl optionally substituted with C_{1-4}alkyloxy, cyano, amino, mono- or di(C_{1-4}alkyl)amino or aminocarbonyl; C_{1-4}alkylcarbonyl; C_{1-4}alkyloxycarbonyl; aminocarbonyl; mono- or di(C_{1-4}alkyl)aminocarbonyl;

R^{12} represents hydrogen or C_{1-4}alkyl;

R^{13} and R^{14} each independently represent C_{1-6}alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl; C_{2-6}alkenyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl; C_{2-6}alkynyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl;

R^{15} represents C_{1-6}alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl;

R^{16} represents C_{1-6}alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl; or R^7;

-C-D- represents a bivalent radical of formula

-N=CH-NR^{17}- (c-1); or

-NR^{17}-CH=N- (c-2);

R^{17} represents hydrogen; C_{1-6}alkyl optionally substituted with hydroxy, cyano, aminocarbonyl, mono-or di(C_{1-4}alkyl)aminocarbonyl, C_{1-4}alkyloxycarbonyl or aryl;

p represents an integer of value 1 or 2;

aryl represents phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, aminoC_{1-6}alkyl, mono or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, C_{1-6}alkylcarbonyl, C_{3-7}cycloalkyl, C_{1-6}alkyloxy, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylthio, cyano, nitro, polyhaloC_{1-6}alkyl, polyhaloC_{1-6}alkyloxy, aminocarbonyl, R^7 or -X_3-R^7;

provided that when A represents a radical of formula (a) then B represents a radical of formula (b) and when A represents a radical of formula (b) then B represents a radical of formula (a).

2. (Original) A compound as defined in claim 1 provided that when R^2 represents aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl then R^3 represents cyano; -C(=O)-R^{15};

-CH=N-NH-C(=O)-R^{16}; C_{1-6}alkyl substituted with one or more substituents each independently selected from R^{3b}; C_{1-6}alkyloxy substituted with one or more substituents each independently selected from R^{3a}; C_{1-6}alkyloxyC_{1-6}alkyl optionally substituted with one or more substituents each independently selected from R^{3a}; C_{2-6}alkenyl optionally substituted with one or more substituents each independently selected from R^{3a}; C_{2-6}alkynyl optionally substituted with one or more substituents each independently selected from R^{3a}; -C(=N-O-R^8)-C_{1-4}alkyl; R^7 or –X_3-R^7; with R^{3b} representing cyano, hydroxy, NR^9R^{10}, -C(=O)-NR^9R^{10}, -C(=O)-C_{1-6}alkyl, -C(=O)-polyhaloC_{1-6}alkyl, -C(=O)-O-polyhaloC_{1-6}alkyl or R^7.

3. (Original) A compound according to claim 2 wherein the compound has the formula



(I-A)

a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof,
wherein R^1, R^2, R^3, R^4, ring E, ring F, C, D and m are as defined in claim 1.

4. (Original) A compound according to claim 3 wherein the compound of formula (I-A) has the formula



(I-A-2)

a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof,
wherein R^1, R^2, R^3, R^4, ring E, ring F, C and D are as defined in claim 1.

5. (Original) A compound according to claim 2 wherein the compound has the formula



(I-B)

a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof,

wherein R^1, R^2, R^3, R^4, ring E, ring F, C, D and m are as defined in claim 1.

6. (Original) A compound according to claim 5 wherein the compound of formula (I-B) has the formula



(I-B-2)

a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof,
wherein R^1, R^2, R^3, R^4, ring E, ring F, C and D are as defined in claim 1.

7. (Currently Amended) A compound according to claim 2~~any one of claims 2 to 6~~ wherein ring E is phenyl.

8. (Currently Amended) A compound according to claim 2~~any one of claims 2 to 7~~ wherein ring F is phenyl.

9. (Original) A compound according to claim 2 wherein the compound has the formula



(I')

a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein
$-a^1=a^2-C(R^2)=a^3-a^4=$ represents a bivalent radical of formula

$-CH=CH-C(R^2)=CH-CH=$ (a-1);
$-N=CH-C(R^2)=CH-CH=$ (a-2);
$-CH=N-C(R^2)=CH-CH=$ (a-3);

-N=CH-C(R^2)=N-CH= (a-4);

-N=CH-C(R^2)=CH-N= (a-5);

-CH=N-C(R^2)=N-CH= (a-6); or

-N=N-C(R^2)=CH-CH= (a-7);

-b^1=b^2-b^3=b^4- represents a bivalent radical of formula

-CH=CH-CH=CH- (b-1);

-N=CH-CH=CH- (b-2);

-N=CH-N=CH- (b-3);

-N=CH-CH=N- (b-4); or

-N=N-CH=CH- (b-5);

-C-D- represents a bivalent radical of formula

-N=CH-NR^{17}- (c-1); or

-NR^{17}-CH=N- (c-2);

m represents an integer of value 1, 2, 3 and in case -b^1=b^2-b^3=b^4- is (b-1), then m may also be 4;

R^1 represents hydrogen; aryl; formyl; C_{1-6}alkylcarbonyl; C_{1-6}alkyloxycarbonyl; C_{1-6}alkyl optionally substituted with formyl, C_{1-6}alkylcarbonyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylcarbonyloxy; or C_{1-6}alkyloxyC_{1-6}alkylcarbonyl substituted with C_{1-6}alkyloxycarbonyl;

R^2 represents cyano; aminocarbonyl; mono- or di(C_{1-4}alkyl)aminocarbonyl; C_{1-6}alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl; C_{2-6}alkenyl substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl; or C_{2-6}alkynyl substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl;

X_1 represents –NR^5-, -NH-NH-, -N=N-, -O-, -C(=O)-, C_{1-4}alkanediyl, -CHOH-, -S-, -$S(=O)_p$-, -X_2-C_{1-4}alkanediyl- or –C_{1-4}alkanediyl-X_2-;

X_2 represents –NR^5-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -$S(=O)_p$-;

R^3 represents NHR^{13}; $NR^{13}R^{14}$; -C(=O)-NHR^{13}; -C(=O)-$NR^{13}R^{14}$; -C(=O)-R^{15}; -CH=N-NH-C(=O)-R^{16}; cyano; halo; C_{1-6}alkyl; polyhaloC_{1-6}alkyl; C_{1-6}alkyl substituted with one or more substituents each independently selected from cyano, NR^9R^{10}, -C(=O)-NR^9R^{10}, -C(=O)-C_{1-6}alkyl or R^7; C_{1-6}alkyl substituted with hydroxy and a second substituent selected from cyano, NR^9R^{10}, -C(=O)-NR^9R^{10}, -C(=O)-C_{1-6}alkyl or R^7; C_{1-6}alkyloxyC_{1-6}alkyl optionally substituted with one or more substituents each independently selected from cyano, NR^9R^{10}, -C(=O)-NR^9R^{10}, -C(=O)-C_{1-6}alkyl or R^7; C_{1-6}alkyloxy optionally substituted with one or more substituents each independently selected from cyano, NR^9R^{10}, -C(=O)-NR^9R^{10}, -C(=O)-C_{1-6}alkyl or R^7; C_{2-6}alkenyl optionally substituted

with one or more substituents each independently selected from halo, cyano, NR^9R^{10}, -C(=O)-NR^9R^{10}, -C(=O)-C_{1-6}alkyl or R^7; C_{2-6}alkynyl optionally substituted with one or more substituents each independently selected from halo, cyano, NR^9R^{10}, -C(=O)-NR^9R^{10}, -C(=O)-C_{1-6}alkyl or R^7; -C(=N-O-R^8)-C_{1-4}alkyl; R^7 or $-X_3-R^7$;

X_3 is $-NR^5$-, -NH-NH-, -N=N-, -O-, -C(=O)-, -S-, -S(=O)$_p$-, -X_{4b}-C_{1-4}alkanediyl-, -C_{1-4}alkanediyl-X_{4a}-, $-C_{1-4}$alkanediyl-X_{4b}-C_{1-4}alkanediyl, -C(=N-OR^8)-C_{1-4}alkanediyl-;

with X_{4a} being -NH-NH-, -N=N-, -O-, -C(=O)-, -S-, -S(=O)$_p$-; and

with X_{4b} being -NH-NH-, -N=N-, -C(=O)-, -S-, -S(=O)$_p$-;

each R^4 independently represents halo, hydroxy, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{1-6}alkyloxy, hydroxyC_{1-6}alkyl, aminoC_{1-6}alkyl, cyano, nitro, polyhaloC_{1-6}alkyl, polyhaloC_{1-6}alkyloxy, aminocarbonyl, mono- or di(C_{1-4}alkyl)aminocarbonyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylcarbonyl, formyl, amino, mono- or di(C_{1-4}alkyl)amino or R^7;

R^5 is hydrogen; aryl; formyl; C_{1-6}alkylcarbonyl; C_{1-6}alkyloxycarbonyl; C_{1-6}alkyl optionally substituted with formyl, C_{1-6}alkylcarbonyl, C_{1-6}alkyloxycarbonyl or C_{1-6}alkylcarbonyloxy; or C_{1-6}alkyloxyC_{1-6}alkylcarbonyl substituted with C_{1-6}alkyloxycarbonyl;

R^6 is C_{1-4}alkyl, amino, mono- or di(C_{1-4}alkyl)amino or polyhaloC_{1-4}alkyl;

R^7 is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted where possible with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, aminoC_{1-6}alkyl, mono or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, formyl, C_{1-6}alkylcarbonyl, C_{3-7}cycloalkyl, C_{1-6}alkyloxy, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylthio, cyano, nitro, polyhaloC_{1-6}alkyl, polyhaloC_{1-6}alkyloxy, aminocarbonyl, -CH(=N-O-R^8), R^{7a}, $-X_3-R^{7a}$ or R^{7a}-C_{1-4}alkanediyl-;

R^{7a} is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted where possible with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, aminoC_{1-6}alkyl, mono or di(C_{1-6}alkyl)aminoC_{1-}

$_{6}$alkyl, formyl, C_{1-6}alkylcarbonyl, C_{3-7}cycloalkyl, C_{1-6}alkyloxy, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylthio, cyano, nitro, polyhaloC_{1-6}alkyl, polyhaloC_{1-6}alkyloxy, aminocarbonyl, or -CH(=N-O-R^8);

R^8 is hydrogen, C_{1-4}alkyl optionally substituted with aryl, or aryl;

R^9 and R^{10} each independently are hydrogen; C_{1-6}alkyl; C_{1-6}alkylcarbonyl; C_{1-6}alkyloxycarbonyl; amino; mono- or di(C_{1-6}alkyl)amino; mono- or di(C_{1-6}alkyl)aminocarbonyl; -CH(=NR^{11}) or R^7, wherein each of the aforementioned C_{1-6}alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C_{1-6}alkyloxy, hydroxyC_{1-6}alkyloxy, carboxyl, C_{1-6}alkyloxycarbonyl, cyano, amino, imino, mono- or di(C_{1-4}alkyl)amino, polyhaloC_{1-4}alkyl, polyhaloC_{1-4}alkyloxy, polyhaloC_{1-4}alkylthio, -S(=O)$_p$$R^6$, -NH-S(=O)$_p$$R^6$, -C(=O)$R^6$, -NHC(=O)H, -C(=O)NHNH$_2$, -NHC(=O)$R^6$,-C(=NH)$R^6$, R^7; or

R^9 and R^{10} may be taken together to form a bivalent or trivalent radical of formula

-CH_2-CH_2-CH_2-CH_2- (d-1);

-CH_2-CH_2-CH_2-CH_2-CH_2- (d-2);

-CH_2-CH_2-O-CH_2-CH_2- (d-3);

-CH_2-CH_2-S-CH_2-CH_2- (d-4);

-CH_2-CH_2-NR^{12}-CH_2-CH_2- (d-5);

-CH_2-CH=CH-CH_2- (d-6); or

=CH-CH=CH-CH=CH- (d-7);

R^{11} represents cyano; C_{1-4}alkyl optionally substituted with C_{1-4}alkyloxy, cyano, amino, mono- or di(C_{1-4}alkyl)amino or aminocarbonyl; C_{1-4}alkylcarbonyl; C_{1-4}alkyloxycarbonyl; aminocarbonyl; mono- or di(C_{1-4}alkyl)aminocarbonyl;

R^{12} represents hydrogen or C_{1-4}alkyl;

R^{13} and R^{14} each independently represent C_{1-6}alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl; C_{2-6}alkenyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl; C_{2-6}alkynyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl;

R^{15} represents C_{1-6}alkyl substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl;

R^{16} represents C_{1-6}alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl; or R^7;

R^{17} represents hydrogen; C_{1-6}alkyl; or C_{1-6}alkyl substituted with aryl;

p is 1 or 2;

aryl represents phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, aminoC_{1-6}alkyl, mono or di(C_{1-6}alkyl)aminoC_{1-6}alkyl, C_{1-6}alkylcarbonyl, C_{3-7}cycloalkyl, C_{1-6}alkyloxy, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylthio, cyano, nitro, polyhaloC_{1-6}alkyl, polyhaloC_{1-6}alkyloxy, aminocarbonyl, R^7 or $-X_3-R^7$;

provided that when R^2 represents aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl then R^3 represents $-C(=O)-R^{15}$; $-CH=N-NH-C(=O)-R^{16}$; cyano; C_{1-6}alkyl substituted with one or more substituents each independently selected from cyano, NR^9R^{10}, $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$alkyl or R^7; C_{1-6}alkyl substituted with hydroxy and a second substituent selected from cyano, NR^9R^{10}, $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$alkyl or R^7; C_{1-6}alkyloxyC_{1-6}alkyl optionally substituted with one or more substituents each independently selected from cyano, NR^9R^{10}, $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$alkyl or R^7; C_{1-6}alkyloxy substituted with one or more substituents each independently selected from cyano, NR^9R^{10}, $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$alkyl or R^7; C_{2-6}alkenyl optionally substituted with one or more substituents each independently selected from halo, cyano, NR^9R^{10}, $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$alkyl or R^7;

C_{2-6}alkynyl optionally substituted with one or more substituents each independently selected from halo, cyano, NR^9R^{10}, $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$alkyl or R^7; $-C(=N-O-R^8)-C_{1-4}$alkyl; R^7 or $-X_3-R^7$.

10. (Currently Amended) A compound according to claim 2~~any one of claims 2 to 9~~ wherein R^2 represents cyano; aminocarbonyl; mono- or di(C_{1-4}alkyl)aminocarbonyl; C_{1-6}alkyl substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl; C_{2-6}alkenyl substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl; or C_{2-6}alkynyl substituted with cyano, aminocarbonyl or mono- or di(C_{1-4}alkyl)aminocarbonyl.

11. (Currently Amended) A compound according to claim 2~~any one of claims 2 to 10~~ wherein R^2 represents cyano or aminocarbonyl.

12. (Currently Amended) A compound according to claim 2~~any one of claims 2 to 11~~ wherein R^3 is cyano; aminocarbonyl; C_{1-6}alkyl optionally substituted with cyano or aminocarbonyl;
C_{1-6}alkyloxy optionally substituted with cyano or aminocarbonyl; C_{2-6}alkenyl substituted with cyano or aminocarbonyl.

13. (Currently Amended) A compound according to claim 2 ~~any one of claims 2 to 9~~ wherein m is 2; R^1 represents hydrogen; R^2 represents cyano, aminocarbonyl or C_{1-6}alkyl; R^3 represents cyano;
C_{1-6}alkyl; C_{1-6}alkyl substituted with cyano; C_{1-6}alkyloxy optionally substituted with cyano; C_{2-6}alkenyl substituted with cyano or -C(=O)-NR^9R^{10}; each R^4 independently represents halo, C_{1-6}alkyl or C_{1-6}alkyloxy; X_1 represents –NR^5- or -O-; R^5 represents hydrogen; R^9 and R^{10} each independently are hydrogen or C_{1-6}alkyl; or R^9 and R^{10} may be taken together to form a bivalent radical of formula -CH_2-CH_2-O-CH_2-CH_2- (d-3); R^{17} is hydrogen; C_{1-6}alkyl optionally substituted with hydroxy, cyano, aminocarbonyl, C_{1-4}alkyloxycarbonyl or aryl; aryl is phenyl substituted with C_{1-6}alkyloxy.

14. (Currently Amended) A compound ~~according to claim 2 wherein the compound is~~ selected from the group consisting of:


;


;


;


;

 ;	 ;
 ;	 ;
 ;	 ;
 ;	 ;
 ;	 ;



; and

a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof.

15. (Cancelled).

16. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as claimed in claim 1 ~~any one of claims 2 to 14~~.

17. (Currently Amended) A process for preparing a pharmaceutical composition according to claim 16 comprising ~~characterized in that~~ a therapeutically effective amount of a compound as claimed in claim 1~~any one of claims 2 to 14 is~~ intimately mixed with a pharmaceutically acceptable carrier.

18. (Currently Amended)A process for preparing a compound as claimed in claim 2, ~~characterized by~~ comprsing:

a) reacting an intermediate of formula (II-a) or (II-b) with an intermediate of formula (III) in the presence of a suitable catalyst, a suitable ligand, a suitable base, and a suitable solvent,



(II-a) (III) (I-a)



(II-b) (III) (I-b)

with W_1 representing a suitable leaving group, R^{17b} representing C_{1-6}alkyl optionally substituted with aryl, and A and B being defined as in claim 2;

b) reacting an intermediate of formula (II'-a) or (II'-b) with an intermediate of formula (III') in the presence of a suitable catalyst, a suitable ligand, a suitable base, and a suitable solvent,



(II'-a) (III') (I-a)



(II'-b) (III') (I-b)

with W_1 representing a suitable leaving group, R^{17b} representing C_{1-6}alkyl optionally substituted with aryl, and A and B being defined as in claim 2;

c) by converting a compound of formula (I-a) or (I-b) into a compound of formula (I-c) and (I-d) by reaction with a suitable acid,



(I-a) (I-c)



(I-b) (I-d)

with R^{17b} representing C_{1-6}alkyl optionally substituted with aryl, and A and B being defined as in claim 2;

d) converting a compound of formula (I-c) into a compound of formula (I-e) by reaction with an intermediate of formula R^{17c}-W_2 in the presence of a suitable base and a suitable solvent,



(I-c) (I-e)

with W_2 representing a suitable leaving group, R^{17c} representing C_{1-6}alkyl optionally substituted with cyano or C_{1-4}alkyloxycarbonyl, and A and B being defined as in claim 2;

e) converting a compound of formula (I-e-1) into a compound of formula (I-f), by reaction with NH_3 in the presence of a suitable solvent,



(I-e-1) (I-f)

with A and B being defined as in claim 2;

f) converting a compound of formula (I-e-1) into a compound of formula (I-g), by reaction with $NaBH_4$ in the presence of a suitable solvent,



(I-e-1) (I-g)

with A and B being defined as in claim 2;

g) converting a compound of formula (I-f) into a compound of formula (I-h), by reaction with $POCl_3$ in the presence of a suitable solvent,



(I-f) (I-h)

with A and B being defined as in claim 2;

or, if desired, further converting compounds of formula (I) into each other following art-known transformations; or further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or conversely, converting the acid addition salt form into the free base by treatment with alkali; or, if desired, preparing stereochemically isomeric forms, *N*-oxide forms or quaternary amines thereof.

19. (Currently Amended) A product containing (a) a compound as defined in claim 1 ~~any one of claims 1 to 14~~, and (b) another antiretroviral compound, as a combined preparation for simultaneous, separate or sequential use in the treatment of HIV infection.

20. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound as defined in claim 1 ~~any one of claims 1 to 14~~, and (b) another antiretroviral compound.

21. (New) A product containing (a) a compound as defined in claim 14, and (b) another antiretroviral compound, as a combined preparation for simultaneous, separate or sequential use in the treatment of HIV infection.

22. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound as defined in claim 14 and (b) another antiretroviral compound.

23. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as claimed in claim 14.

24. (New) A process for preparing a pharmaceutical composition according to claim 23 comprising a therapeutically effective amount of a compound as claimed in claim 14-intimately mixed with a pharmaceutically acceptable carrier.